World Intellectual Property Day | DeJin Medical Earns National IP Management System Certification Amid IPO Filing
Valgen Medtech
Minimally Invasive Interventional Device Developer
On the occasion of the 26th World Intellectual Property Day, Valgen Medtech, with its rigorous intellectual property management system and outstanding independent innovation capabilities, successfully passed the review and officially obtained the certification for the GB/T 29490-2023 Intellectual Property Compliance Management System. The company was also awarded the "Enterprise Intellectual Property Compliance Management System Certification Certificate."
This certification covers the entire process of intellectual property management for the research, development, production, and sales of the company's core products. It marks that Valgen Medtech has reached the national standard in the full lifecycle of intellectual property creation, utilization, protection, and management, entering a new phase of systematic and compliant operations.
As an innovative leader in the field of atrioventricular valve interventional treatment, Valgen Medtech always adheres to the principle of driving clinical value through original innovation.
Global Patent Layout:As of January 2026, Valgen Medtech has applied for over 600 patents globally.
Core Technology Breakthrough:More than 200 authorized invention patents, covering the basic principles, core structures, and key technical features of the products.
A global patent layout provides Valgen Medtech with clear and compliant access guarantees for clinical advancement and business expansion in key global markets.
Intellectual property is not only the carrier of technological innovation but also the core asset that determines the global competitive landscape of enterprises. Through this certification, Valgen Medtech has further solidified its full lifecycle IP risk control system, which covers R&D, production, and commercialization, ensuring that core technology assets continue to deliver value within a compliant framework.
In the future, Valgen Medtech will take this certification as a new starting point and continue to deepen its expertise in the field of atrioventricular valve interventional treatment. Through the integration of compliance-driven mechanisms, risk prevention and control, and value empowerment within its intellectual property compliance management system, the company will accelerate the transformation of leading technologies into clinical advantages, providing global patients with more precise and safer interventional treatment solutions.
——— Previous Review ———
